728

Search Sites

Google

Friday, February 2, 2018

Adipogenic Differentiation from Mesenchymal Stem Cell (MSCs) Involves PTHrP and PPAR-γ Pathways

Background: The potential use of cell-based therapy is one of the most exciting advances in the field of translational medicine to treat various pathological conditions that have been untreatable up to now. Chronic lung disease is rapidly becoming the primary cause of death in the US. Currently, there is no intervention that can either arrest or cure evolving or established chronic lung diseases. Knowledge of the intrinsic molecular mechanisms that allow for resistance to inflammation and recruitment of stem cells for repair would allow for the engineering of such cells for effective treatment.

MSCs are bone marrow non-haematopoietic stem cells that are multipotent and can differentiate into bone, cartilage and connective tissues. Moreover MSCs present many advantages as facilities to culture or to transform genetically. We have discovered that Parathyroid Hormone-related Protein (PTHrP) and PPAR-r drive the key homeostatic lung epithelial-mesenchymal interactions, resulting in the differentiation of alveolar interstitial lipofibroblasts that are essential for normal lung development and its repair following injury. In this paper, we try to isolate CD45 (-) CD73 (+) CD90 (+) MSCs from 6 weeks old rats and further induce such cells into adipogenic cells. Meanwhile, we try to confirm our hypothesis that PTHrP and PPAR-γ related pathways are involved in the MSCs differential procedure.

Methods:  Femurs and tibias were aseptically harvested from 6 weeks old Wistar rats. Whole bone marrow plugs were obtained by flushing the bone marrow cavity with an 18-gauge needle set with a syringe filled with α-MEM medium. Second passage of adherent MSCs were analyzed by flow cytometry after staining with fluorochrome conjugated CD45, CD73 and CD90 antibodies. These MSCs had been inducing with induction buffer (α-MEM enriched with 10% FBS, 10 μg/ml insulin, 1 μM dexamethasone, and 0.5 mM 3-isobutyl-1-methylxanthine for 11 days. Oil Red O stain was processed to show the efficacy of adipocytic induction. Total RNA was extracted with one step procedure, and RT-PCR was used to probe PPAR-γ expression. Also, we investigated the muscular marker, α-SMA, by Western blot hybridization.

Results: The BM-derived MSCs expressed a set of specific markers that are well-known to define MSCs, including 99.36% CD45 (-), 59.92 CD73 (+), and 91.1% CD90 (+). Adipocytic differentiation of rat MSCs was induced under the conditions described above. Morphologically, the spindle small MSCs changed into large round cells with alveolus-like distribution.  Appearance of cell fat granules was observed after 11 days incubation. More than 50% of the induced cells displayed Oil Red O+ lipid granules, and 500 nM PTHrP and 1 nM RGZ obviously increased the Oil Red O+ cells with more and larger lipid granules. PPAR-γ, a marker of adipocylic differentian, was over expressed after induction with/without enhancement (PTHrP or RGZ, or both). On the other hand, the muscular marker, α-SMA had much lower expression after the induction. The groups with PTHrP and/or RGZ had significant weaker α-SMA expression, comparatively.


Conclusion: Adherent MSCs isolated from 6 weeks old rat can be directionally induced into adipocytic cells. PTHrP and PPAR-γ stimulator RGZ can enhance this kind of differentiation. 

Protein Purification Protocols

Author(s): Shawn Doonan, Paul Cutler
Pub. Date: Dec-12-2003; DOI: 10.1385/1-59259-655-X:1; Page Range: 1-13
Author(s): J. Mark Skehel
Pub. Date: Dec-12-2003; DOI: 10.1385/1-59259-655-X:15; Page Range: 15-20
Author(s): Roger J. Fido, E. N. Mills, Neil M. Rigby, Peter R. Shewry
Pub. Date: Dec-12-2003; DOI: 10.1385/1-59259-655-X:21; Page Range: 21-27
Author(s): Anne F. McGettrick, D. Margaret Worrall
Pub. Date: Dec-12-2003; DOI: 10.1385/1-59259-655-X:29; Page Range: 29-35
Author(s): Paul D. Bridge, Tetsuo Kokubun, Monique S. Simmonds
Pub. Date: Dec-12-2003; DOI: 10.1385/1-59259-655-X:37; Page Range: 37-46
Author(s): Norma M. Ryan
Pub. Date: Dec-12-2003; DOI: 10.1385/1-59259-655-X:47; Page Range: 47-52
Author(s): Alyson K. Tobin, Caroline G. Bowsher
Pub. Date: Dec-12-2003; DOI: 10.1385/1-59259-655-X:53; Page Range: 53-63
Author(s): William S. Pierpoint
Pub. Date: Dec-12-2003; DOI: 10.1385/1-59259-655-X:65; Page Range: 65-74
Author(s): Robert J. Beynon, Simon Oliver
Pub. Date: Dec-12-2003; DOI: 10.1385/1-59259-655-X:75; Page Range: 75-84
Author(s): Shawn Doonan
Pub. Date: Dec-12-2003; DOI: 10.1385/1-59259-655-X:85; Page Range: 85-90
Author(s): Shawn Doonan
Pub. Date: Dec-12-2003; DOI: 10.1385/1-59259-655-X:91; Page Range: 91-99
Author(s): Paul Schratter
Pub. Date: Dec-12-2003; DOI: 10.1385/1-59259-655-X:101; Page Range: 101-116
Author(s): Shawn Doonan
Pub. Date: Dec-12-2003; DOI: 10.1385/1-59259-655-X:117; Page Range: 117-124
Author(s): Chris Selkirk
Pub. Date: Dec-12-2003; DOI: 10.1385/1-59259-655-X:125; Page Range: 125-131
Author(s): Paul A. O’Farrell
Pub. Date: Dec-12-2003; DOI: 10.1385/1-59259-655-X:133; Page Range: 133-138
Author(s): Paul Cutler
Pub. Date: Dec-12-2003; DOI: 10.1385/1-59259-655-X:139; Page Range: 139-149
Author(s): Anne F. McGettrick, D. Margaret Worrall
Pub. Date: Dec-12-2003; DOI: 10.1385/1-59259-655-X:151; Page Range: 151-157
Author(s): Iris West, Owen Goldring
Pub. Date: Dec-12-2003; DOI: 10.1385/1-59259-655-X:159; Page Range: 159-166
Author(s): Paul Cutler
Pub. Date: Dec-12-2003; DOI: 10.1385/1-59259-655-X:167; Page Range: 167-177
Author(s): Tai-Tung Yip, T. William Hutchens
Pub. Date: Dec-12-2003; DOI: 10.1385/1-59259-655-X:179; Page Range: 179-190
Author(s): Shawn Doonan
Pub. Date: Dec-12-2003; DOI: 10.1385/1-59259-655-X:191; Page Range: 191-194
Author(s): Paul Matejtschuk
Pub. Date: Dec-12-2003; DOI: 10.1385/1-59259-655-X:195; Page Range: 195-204
Author(s): Jane A. Irwin, Keith F. Tipton
Pub. Date: Dec-12-2003; DOI: 10.1385/1-59259-655-X:205; Page Range: 205-223
Author(s): Reiner Westermeier
Pub. Date: Dec-12-2003; DOI: 10.1385/1-59259-655-X:225; Page Range: 225-232
Author(s): Timothy J. Mantle, Patricia Noone
Pub. Date: Dec-12-2003; DOI: 10.1385/1-59259-655-X:233; Page Range: 233-237
Author(s): Paul Cutler
Pub. Date: Dec-12-2003; DOI: 10.1385/1-59259-655-X:239; Page Range: 239-252
Author(s): David Sheehan, Siobhan O’Sullivan
Pub. Date: Dec-12-2003; DOI: 10.1385/1-59259-655-X:253; Page Range: 253-258
Author(s): William A. Neville
Pub. Date: Dec-12-2003; DOI: 10.1385/1-59259-655-X:259; Page Range: 259-281
Author(s): Kay Ohlendieck
Pub. Date: Dec-12-2003; DOI: 10.1385/1-59259-655-X:283; Page Range: 283-293
Author(s): Kay Ohlendieck
Pub. Date: Dec-12-2003; DOI: 10.1385/1-59259-655-X:295; Page Range: 295-300
Author(s): Kay Ohlendieck
Pub. Date: Dec-12-2003; DOI: 10.1385/1-59259-655-X:301; Page Range: 301-308
Author(s): Ciarán Ó’Fágáin
Pub. Date: Dec-12-2003; DOI: 10.1385/1-59259-655-X:309; Page Range: 309-321
Author(s): Ciarán óFágáin
Pub. Date: Dec-12-2003; DOI: 10.1385/1-59259-655-X:323; Page Range: 323-337
Author(s): Michael J. Dunn
Pub. Date: Dec-12-2003; DOI: 10.1385/1-59259-655-X:339; Page Range: 339-343
Author(s): Michael J. Dunn
Pub. Date: Dec-12-2003; DOI: 10.1385/1-59259-655-X:345; Page Range: 345-352
Author(s): Neil A. Jones
Pub. Date: Dec-12-2003; DOI: 10.1385/1-59259-655-X:353; Page Range: 353-359
Author(s): Xun Zuo, David W. Speicher
Pub. Date: Dec-12-2003; DOI: 10.1385/1-59259-655-X:361; Page Range: 361-375
Author(s): Shawn Doonan
Pub. Date: Dec-12-2003; DOI: 10.1385/1-59259-655-X:377; Page Range: 377-387
Author(s): Jacek Mozdzanowski, Sudhir Burman
Pub. Date: Dec-12-2003; DOI: 10.1385/1-59259-655-X:389; Page Range: 389-410
Author(s): Dean E. McNulty, J. Randall Slemmon
Pub. Date: Dec-12-2003; DOI: 10.1385/1-59259-655-X:411; Page Range: 411-423
Author(s): Rod Watson, Tim Nadler
Pub. Date: Dec-12-2003; DOI: 10.1385/1-59259-655-X:425; Page Range: 425-445
Author(s): David J. Bell
Pub. Date: Dec-12-2003; DOI: 10.1385/1-59259-655-X:447; Page Range: 447-454
Author(s): Julian Bonnerjea
Pub. Date: Dec-12-2003; DOI: 10.1385/1-59259-655-X:455; Page Range: 455-462
Author(s): Karl Prince, Martin Smith
Pub. Date: Dec-12-2003; DOI: 10.1385/1-59259-655-X:463; Page Range: 463-480


WHAT IS HIV TESTING

WHAT IS HIV TESTING?

HIV testing tells you if you are infected with the Human Immunodeficiency Virus (HIV) which causes AIDS.  These tests look for “antibodies” to HIV.  Antibodies are proteins produced by the immune system to fight a specific germ.

Other “HIV” tests are used when people already know they are infected with HIV. These measure how quickly the virus is multiplying (a viral load test, see fact sheet 125) or the health of your immune system (a CD4 count, see fact sheet 124). 


HOW DO I GET TESTED?

In September 2006, the US Centers for Disease Control recommended routine HIV screening of people in healthcare settings. This should result in more general HIV testing in the US.

You can arrange for HIV testing at any Public Health office, or at your doctor’s office. Test results are usually available within two weeks. In the US, call the National AIDS Hotline, (800) 342-2437.

The most common HIV test is a blood test.  Newer tests can detect HIV antibodies in mouth fluid (not the same as saliva), a scraping from inside the cheek, or urine.  “Rapid” HIV test results are available within 10 to 30 minutes after a sample is taken.  One of these tests has produced a high rate of false positives. A positive result on any HIV test should be confirmed with a second test.

Home test kits: You can’t test yourself for HIV at home.  The “Home Access” test kit is only designed to collect a sample of your blood.  You send the sample to a laboratory where it is tested for HIV.


WHEN SHOULD I GET TESTED?
If you become infected with HIV, it usually takes between three weeks and two months for your immune system to produce antibodies to HIV.  If you think you were exposed to HIV, you should wait for two months before being tested.  You can also test right away and then again after two or three months.  During this “window period” an antibody test may give a negative result, but you can transmit the virus to others if you are infected. 

About 5% of people take longer than two months to produce antibodies.  There is one documented case of a person exposed to HIV and hepatitis C at the same time.  Antibodies to HIV were not detected until one year after exposure.  Testing at 3 and 6 months after possible exposure will detect almost all HIV infections.  However, there are no guarantees as to when an individual will produce enough antibodies to be detected by an HIV test.  If you have any unexplained symptoms, talk with your health care provider and consider re-testing for HIV.


DO ANY TESTS WORK SOONER AFTER INFECTION?
Viral load tests detect pieces of HIV genetic material.  They show up before the immune system manufactures antibodies.  Also, in early 2002, the FDA approved “nucleic acid testing.”  It is similar to viral load testing.  Blood banks use it to screen donated blood. 

The viral load or nucleic acid tests are generally not used to see if someone has been infected with HIV because they are much more expensive than an antibody test.  They also have a slightly higher error rate.


WHAT DOES IT MEAN IF I TEST POSITIVE?

A positive test result means that you have HIV antibodies, and are infected with HIV. You will get your test result from a counselor who should tell you what to expect, and where to get health services and emotional support.

Testing positive does not mean that you have AIDS (See Fact Sheet 101, What is AIDS?).  Many people who test positive stay healthy for several years, even if they don’t start taking medication right away. 

If you test negative and you have not been exposed to HIV for at least three months, you are not infected with HIV.  Continue to protect yourself from HIV infection (See Fact Sheet 103, Stopping the Spread of HIV).


CAN I KEEP THE TEST RESULT CONFIDENTIAL?

You can be tested anonymously in many places.  You do not have to give your name when you are tested at a public health office, or when you receive the test results.  You can be tested anonymously for HIV as many times as you want.

If you get a positive HIV test that is not anonymous, or if you get any medical services for HIV infection, your name may be reported to the Department of Health. 
The Centers for Disease Control (CDC) proposed in late 1998 that all states keep track of the names of HIV-infected people.  This proposal has not yet taken effect. 


HOW ACCURATE ARE THE TESTS?

Antibody test results for HIV are accurate more than 99.5% of the time. Before you get the results, the test has usually been done two or more times.  The first test is called an “EIA” or “ELISA” test.  Before a positive ELISA test result is reported, it is confirmed by another test called a “Western Blot”. 

Two special cases can give false results:

Children born to HIV-positive mothers may have false positive test results for several months because mothers pass infection-fighting antibodies to their newborn children.  Even if the children are not infected, they have HIV antibodies and will test positive.  Other tests, such as a viral load test, must be used.

As mentioned above, people who were recently infected may test negative if they get tested too soon after being infected with HIV. 


THE BOTTOM LINE

HIV testing generally looks for HIV antibodies in the blood, or saliva or urine.  The immune system produces these antibodies to fight HIV.  It usually takes two to three months for them to show up.  In rare cases, it can take longer than three months.  During this “window period” you may not test positive for HIV even if you are infected.  Normal HIV tests don’t work for newborn children of HIV-infected mothers.

In many places, you can get tested anonymously for HIV.  Once you test positive and start to receive health care for HIV infection, your name may be reported to the Department of Health.  These records are kept confidential.

A positive test result does not mean that you have AIDS.  If you test positive, you should learn more about HIV and decide how to take care of your health.

AIDS MYTHS AND MISUNDERSTANDINGS

WHY ARE THERE SO MANY AIDS MYTHS?
When AIDS first became known, it was a very mysterious disease. It caused the death of many people. There are still many unanswered questions about the disease. Many people reacted with fear and came up with stories to back up their fear. Most of these had to do with how easy it was to become infected with HIV. Most of these are not true.


TRANSMISSION MYTHS
Many people believed that HIV and AIDS could be transmitted by a mosquito bite, by sharing a drinking glass with someone with AIDS, by being around someone with AIDS who was coughing, by hugging or kissing someone with AIDS, and so on. See fact sheet 150 for current information on how HIV is transmitted. Transmission can only occur if someone is exposed to blood, semen, vaginal fluid or mother’s milk (see fact sheet 611) from an infected person. There is no documentation of transmission from the tears or saliva of an infected person.

·    Myth: A woman with HIV infection can’t have children without infecting them.
·    Reality: Without any treatment, HIV-infected mothers pass HIV to their newborns about 25% of the time. However, with modern treatments, this rate has dropped to only about 2%. See Fact Sheet 611 for more information about HIV and pregnancy.

·    Myth: HIV is being spread by needles left in theater seats or vending machine coin returns.
·    Reality: There is no documented case of this type of transmission.


MYTHS ABOUT A CURE
It can be very scary to have HIV infection or AIDS. The course of the disease is not very predictable. Some people get very sick in just a few months. Others live healthy lives for 20 years or more. The treatments can be difficult to take, with serious side effects. Not everyone can afford the medications. It’s not surprising that scam artists have come up with several “cures” for AIDS that involve a variety of substances. Unfortunately, none of these “cures” work. See fact sheet 206 for more information on frauds related to AIDS.

A very unfortunate myth in some parts of the world is that having sex with a virgin will cure AIDS. As a result, many young girls have been exposed to HIV and have developed AIDS. There is no evidence to support this belief.

·    Myth: Current medications can cure AIDS. It’s no big deal if you get infected.
·    Reality: today’s medications have cut the death rate from AIDS by about 80%. They are also easier to take than they used to be. However, they still have side effects, are very expensive, and have to be taken every day for the rest of your life. If you miss too many doses, HIV can develop resistance (see fact sheet 126) to the drugs you are taking and they’ll stop working. 


AIDS IS A DEATH SENTENCE
In the 1980s, there was a very high death rate from AIDS. However, medications have improved dramatically and so has the life span of people with HIV infection. If you have access to ARVs and to medical monitoring, there’s no reason you can’t live a long life even with HIV infection or AIDS.


THE GOVERNMENT DEVELOPED AIDS TO REDUCE MINORITY POPULATIONS
The world’s best researchers in government and in private pharmaceutical companies are working hard to try to stop AIDS. The government doesn’t have the capability to create a virus.

Many minorities do not trust the government, especially regarding health care. A recent study in Texas found that as many as 30% of Latinos and African Americans believed that HIV is a government conspiracy to kill minorities. However, it seems that minorities receive a lower level of health care due to the same factors as anyone else: low income, inconvenient health care offices, and so on. Attitudes about health care and health care providers were much less important.


MYTHS ABOUT MEDICATIONS
It has been very challenging for doctors to choose the best anti-HIV medications (ARVs) for their patients. When the first drugs were developed, they had to be taken as many as three times a day. Some drugs had complicated requirements about storage, or what kind of food they had to be taken with (or how long you had to wait after eating before taking a dose.) The reality of ARVs has changed dramatically. However, there are still some myths:

·    Myth: You have to take your doses exactly 12 (or 8, or 24) hours apart.
·    Reality: Medications today are fairly forgiving. Although you will have the most consistent blood levels of your drugs if they are taken at even intervals through the day, they won’t stop working if you’re off by an hour or two. However, people taking Crixivan® (indinavir) without ritonavir need to be very careful about timing.

·    Myth: You have to take 100% of your doses on time or else they’ll stop working.
·    Reality: It’s very important to take AIDS medications correctly. In fact, if you miss more than about 5% of your doses, HIV has an easier time developing resistance (see fact sheet 126) and possibly being able to multiply even when you’re taking ARVs. However, 100% adherence is not realistic for just about anyone. Do the best you can and be sure to let your health care provider what’s going on.

·    Myth: Current drugs are so strong that you can stop taking them (take a drug holiday) with no problem.
·    Reality: Ever since the first AIDS drugs were developed, patients have wanted to stop taking them due to side effects or just being reminded that they had AIDS. There have been many studies of “treatment interruptions” and all of them have shown that stopping your ARVs is very likely to cause problems. You could give the virus a chance to multiply (see fact sheet 125 on the viral load) or your count of CD4 cells (see fact sheet 124) could drop, a sign of immune damage.


·   Myth: AIDS drugs are poison and are more dangerous than the HIV virus. Reality: When the first AIDS drugs became available, they weren’t as good as current medications. People still died of AIDS-related conditions. It’s true that some people get serious side effects from AIDS medications, but the death rate in the US has dropped by about 80%. Researchers are working hard to make HIV treatments easier and safer to use.

Biotech News

Powered by Feedzilla